Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1769-1772

  Neki, Kai ^a   Kawahara, Hidejiro ^a   Watanabe, Kazuhiro ^a   Toyama, Yoichi ^a   Akiba, Tadashi ^a   Yanaga, Katsuhiko ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Circulating tumor cell; Colorectal cancer; Prediction of progression

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PANITUMUMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; KIRSTEN SARCOMA ONCOVIRUS; LIVER METASTASIS; LIVER RESECTION; MALE; PREDICTION; PRIORITY JOURNAL; VIRUS ONCOGENE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TEGAFUR;

EID: 84876767651     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F and Bismuth H: Rescue surgery for unresectable colorectal liver metastasese downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240: 644-657, 2004.
2. Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, Giovannini I and Barone C: Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 11: 318-324, 2007.
3. Sugihara K and Uetake H: Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. J Hepatobilliary Pancreat Sci 19: 523-527, 2012.
4. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Giberg F and Saltz L: XELOX vs. FOLFOX-4 as first-line therapy for metastatic colorectal cancer: N16966 updated results. Br J Cancer 105: 58-64, 2011.
5. Van Cutsem E, Rivera F, Berry S, Kretzshmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeter M, Bridgewater J, Cunningham D; First BEAT investigators: Safety and efficacy of first-line bevacizumab with FOLOFOX, XELOX, FOLFIRI and fluoropyimidines in metastatic colorectal cancer: the BEST study. Ann Oncol 20: 1842-1847, 2009.
6. Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P and Köhne CH: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17: 450-456, 2006. (Pubitemid 43329582)
7. Douillard J Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunnigham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M and Gansert J: Randomized, phase III trail of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28: 4697-4705, 2010.
8. Japanese Society for Cancer of the Colon and Rectum Japanese Classification of Colorectal Carcinoma. Second English Ed. Kanehara Co. Ltd., Tokyo, 2009.
9. Allen-Mersh TG, McCullough TK, Patel H, Wharlon RQ, Glover C and Jonas SK: Role of circulating tumor cells in predicting recurrence after excision of primary colorectal carcinima. Br J Surg 94: 96-105, 2007. (Pubitemid 46142739)
10. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle G V, Tissing H, Terstappen LW and Meropol NJ: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221, 2008.
11. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail N Y, Picus J, Morse MA, Mitchell E, Miller MC, Doyle G V, Tissing H, Terstappen LW and Meropol NJ: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223-1229, 2009.
12. Yalcin S, Kilickap S, Portakal O, Arslan C, Hascelik G and Kutluk T: Determination of circulating tumor cells for detection of colorectal cancer progression or recurrence. Hepatogastroenterol 57: 1395-1398, 2010.
13. Kawahara H, Watanabe K, Toyama Y, Yanagisawa S, Kobayashi S and Yanaga K: Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression. Hepatogastroenterol 59: 2115-2118, 2012.